Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial

{ 'indexed': {'date-parts': [[2022, 8, 26]], 'date-time': '2022-08-26T12:43:06Z', 'timestamp': 1661517786061}, 'reference-count': 30, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 8, 26]], 'date-time': '2022-08-26T00:00:00Z', 'timestamp': 1661472000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 8, 26]], 'date-time': '2022-08-26T00:00:00Z', 'timestamp': 1661472000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [{'name': 'Navamindradhiraj University', 'award': ['171/64']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>The emergent outbreak of coronavirus disease (COVID-19), caused by ' 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement ' 'for therapeutic opportunities to overcome this pandemic. Ivermectin is an antiparasitic drug ' 'that has shown effectiveness against various agents, including SARS-CoV-2. This study aimed ' 'to assess the efficacy of ivermectin treatment compared with the standard of care (SOC) among ' 'people with mild to moderate COVID-19 symptoms.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>In this randomized, double-blind, placebo-controlled, single-center, ' 'parallel-arm, superiority trial among adult hospitalized patients with mild to moderate ' 'COVID-19, 72 patients (mean age 48.57 ± 14.80 years) were randomly assigned to either the ' 'ivermectin (<jats:italic>n</jats:italic>=36) or placebo (<jats:italic>n</jats:italic>=36) ' 'group, along with receiving standard care. We aimed to compare the negativity of reverse ' 'transcription polymerase chain reaction (RT-PCR) result at days 7 and 14 of enrolment as the ' 'primary outcome. The secondary outcomes were duration of hospitalization, frequency of ' 'clinical worsening, survival on day 28, and adverse events.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>At days 7 and 14, no differences were observed in the proportion of ' 'PCR-positive patients (RR 0.97 at day 7 (<jats:italic>p</jats:italic>=0.759) and 0.95 at day ' '14 (<jats:italic>p</jats:italic>=0.813). No significant differences were found between the ' 'groups for any of the secondary endpoints, and no adverse events were reported.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>No difference was found in the proportion of PCR-positive cases after ' 'treatment with ivermectin compared with standard care among patients with mild to moderate ' 'COVID-19 symptoms. However, early symptomatic recovery was observed without side ' 'effects.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Trial registration</jats:title>\n' ' <jats:p>ClinicalTrials.gov NCT05076253. Registered on 8 October 2021, ' 'prospectively.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s13063-022-06649-3', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 26]], 'date-time': '2022-08-26T12:02:55Z', 'timestamp': 1661515375000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a ' 'randomized, double-blind, placebo-controlled trial', 'prefix': '10.1186', 'volume': '23', 'author': [ {'given': 'Anan', 'family': 'Manomaipiboon', 'sequence': 'first', 'affiliation': []}, { 'given': 'Kittisak', 'family': 'Pholtawornkulchai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sujaree', 'family': 'Poopipatpab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Swangjit', 'family': 'Suraamornkul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jakravoot', 'family': 'Maneerit', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wiroj', 'family': 'Ruksakul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Uraporn', 'family': 'Phumisantiphong', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4374-251X', 'authenticated-orcid': False, 'given': 'Thananda', 'family': 'Trakarnvanich', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 8, 26]]}, 'reference': [ { 'key': '6649_CR1', 'unstructured': 'COVID-19 dashboard. 2021. https://coronavirus.jhu.edu/map.html. Accessed ' '20 Nov 2021.'}, { 'key': '6649_CR2', 'doi-asserted-by': 'publisher', 'first-page': '445', 'DOI': '10.1016/j.pt.2014.07.005', 'volume': '30', 'author': 'S Omura', 'year': '2014', 'unstructured': 'Omura S, Crump A. Ivermectin: panacea for resource-poor communities? ' 'Trends Parasitol. 2014;30:445–55. ' 'https://doi.org/10.1016/j.pt.2014.07.005.', 'journal-title': 'Trends Parasitol'}, { 'key': '6649_CR3', 'doi-asserted-by': 'publisher', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'volume': '178', 'author': 'L Caly', 'year': '2020', 'unstructured': 'Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'Res. 2020;178:104787. https://doi.org/10.1016/j.antiviral.2020.104787.', 'journal-title': 'Antiviral Res'}, { 'key': '6649_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1833', 'DOI': '10.1113/JP275236', 'volume': '596', 'author': 'IS Chen', 'year': '2018', 'unstructured': 'Chen IS, Kubo Y. Ivermectin and its target molecules: shared and unique ' 'modulation mechanisms of ion channels and receptors by ivermectin. J ' 'Physiol. 2018;596:1833–45. https://doi.org/10.1113/JP275236.', 'journal-title': 'J Physiol'}, { 'key': '6649_CR5', 'doi-asserted-by': 'publisher', 'first-page': '10', 'DOI': '10.3329/jbcps.v38i0.47512', 'volume': '38', 'author': 'MT Alam', 'year': '2020', 'unstructured': 'Alam MT, Murshed R, Ebhiuyan E, Saber S, Alam RF, Robin RC. A case ' 'series of 100 COVID-19 positive patients treated with combination of ' 'ivermectin and doxycycline. J Bangladesh Coll Phys. 2020;38:10–5. ' 'https://doi.org/10.3329/jbcps.v38i0.47512.', 'journal-title': 'J Bangladesh Coll Phys'}, { 'key': '6649_CR6', 'doi-asserted-by': 'publisher', 'first-page': 'e299', 'DOI': '10.1097/MJT.0000000000001377', 'volume': '28', 'author': 'P Kory', 'year': '2021', 'unstructured': 'Kory P, GU M, Varon J, et al.. Review of the emerging evidence ' 'demonstrating the efficacy of ivermectin in the prophylaxis and ' 'treatment of COVID-19. Am J Ther. 2021;28:e299–318.', 'journal-title': 'Am J Ther'}, { 'key': '6649_CR7', 'doi-asserted-by': 'publisher', 'first-page': '828', 'DOI': '10.1016/j.arbres.2020.08.007', 'volume': '56', 'author': 'MSI Khan', 'year': '2020', 'unstructured': 'Khan MSI, Khan MSI, Debnath CR, Nath PN, Mahtab MA, Nabeka H, et al. ' 'Ivermectin treatment may improve the prognosis of patients with ' 'COVID-19. Arch Bronconeumol. 2020;56:828–30. ' 'https://doi.org/10.1016/j.arbres.2020.08.007.', 'journal-title': 'Arch Bronconeumol'}, { 'key': '6649_CR8', 'doi-asserted-by': 'publisher', 'first-page': '85', 'DOI': '10.1016/j.chest.2020.10.009', 'volume': '159', 'author': 'JC Rajter', 'year': '2021', 'unstructured': 'Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of ' 'ivermectin is associated with lower mortality in hospitalized patients ' 'with coronavirus disease 2019: the ivermectin in COVID nineteen study. ' 'Chest. 2021;159:85–92. https://doi.org/10.1016/j.chest.2020.10.009.', 'journal-title': 'Chest'}, { 'key': '6649_CR9', 'doi-asserted-by': 'publisher', 'first-page': '758', 'DOI': '10.1016/j.jconrel.2020.10.009', 'volume': '329', 'author': 'FR Formiga', 'year': '2021', 'unstructured': 'Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, ' 'Pena L. Ivermectin: an award-winning drug with expected antiviral ' 'activity against COVID-19. J Control Release. 2021;329:758–61. ' 'https://doi.org/10.1016/j.jconrel.2020.10.009.', 'journal-title': 'J Control Release'}, { 'issue': '4', 'key': '6649_CR10', 'doi-asserted-by': 'publisher', 'first-page': 'e434', 'DOI': '10.1097/MJT.0000000000001402', 'volume': '28', 'author': 'A Bryant', 'year': '2021', 'unstructured': 'Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. ' 'Ivermectin for prevention and treatment of COVID-19 infection: a ' 'systematic review, meta-analysis, and trial sequential analysis to ' 'inform clinical guidelines. Am J Ther. 2021;28(4):e434–60. ' 'https://doi.org/10.1097/MJT.0000000000001402.', 'journal-title': 'Am J Ther'}, { 'key': '6649_CR11', 'first-page': '31', 'volume': '9', 'author': 'AZK Chachar', 'year': '2020', 'unstructured': 'Chachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A, Basri R. ' 'Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. Int J Sci. ' '2020;9:31–5.', 'journal-title': 'Int J Sci'}, { 'issue': '7', 'key': '6649_CR12', 'doi-asserted-by': 'publisher', 'first-page': 'CD015017', 'DOI': '10.1002/14651858.CD015017.pub2', 'volume': '7', 'author': 'M Popp', 'year': '2021', 'unstructured': 'Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, et al. ' 'Ivermectin for preventing and treating COVID-19. Cochrane Database Syst ' 'Rev. 2021;7(7):CD015017. https://doi.org/10.1002/14651858.CD015017.pub2 ' 'PMID: 34318930; PMCID: PMC8406455.', 'journal-title': 'Cochrane Database Syst Rev'}, { 'key': '6649_CR13', 'doi-asserted-by': 'publisher', 'unstructured': 'Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus ' 'Disease 2019 (COVID-19): A Perspective from China. Radiology. ' '2020;296(2):E15-E25. https://doi.org/10.1148/radiol.2020200490.', 'DOI': '10.1148/radiol.2020200490'}, { 'key': '6649_CR14', 'doi-asserted-by': 'publisher', 'unstructured': 'Bukhari KHS, Asghar A, Perveen N, Hayat A, Mangat SA, Kamil RB, et al. ' 'Efficacy of ivermectin in COVID-19 patients with mild to moderate ' 'disease. medRxiv 2021. https://doi.org/10.1101/2021.02.02.21250840 ' '[Preprint 5 February 2021]. Ahmed S, Karim MM, Ross AG, Hossain MS, ' 'Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the ' 'treatment of COVID-19 may reduce the duration of illness. Int J Infect ' 'Dis. 2021;103:214–216. https://doi.org/10.1016/j.ijid.2020.11.191.', 'DOI': '10.1101/2021.02.02.21250840 10.1016/j.ijid.2020.11.191'}, { 'key': '6649_CR15', 'doi-asserted-by': 'publisher', 'first-page': '103', 'DOI': '10.4055/cios.2014.6.1.103', 'volume': '6', 'author': 'J Kim', 'year': '2014', 'unstructured': 'Kim J, Shin W. How to do random allocation (randomization). Clin Orthop ' 'Surg. 2014;6:103–9. https://doi.org/10.4055/cios.2014.6.1.103.', 'journal-title': 'Clin Orthop Surg'}, { 'key': '6649_CR16', 'doi-asserted-by': 'publisher', 'first-page': '235', 'DOI': '10.1080/20477724.2021.1890887', 'volume': '115', 'author': 'LEB Galan', 'year': '2021', 'unstructured': 'Galan LEB, Santos NMD, Asato MS, Araújo JV, de Lima Moreira A, Araújo ' 'AMM, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine ' 'or ivermectin in hospitalized patients with severe manifestations of ' 'SARS-CoV-2 infection. Pathog Glob Health. 2021;115:235–42. ' 'https://doi.org/10.1080/20477724.2021.1890887.', 'journal-title': 'Pathog Glob Health'}, { 'key': '6649_CR17', 'doi-asserted-by': 'publisher', 'first-page': '52', 'DOI': '10.1016/j.pulmoe.2020.07.003', 'volume': '27', 'author': 'A Cortegiani', 'year': '2021', 'unstructured': 'Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et ' 'al. Rationale and evidence on the use of tocilizumab in COVID-19: a ' 'systematic review. Pulmonology. 2021;27:52–66. ' 'https://doi.org/10.1016/j.pulmoe.2020.07.003.', 'journal-title': 'Pulmonology'}, { 'key': '6649_CR18', 'unstructured': 'US Food and Drug Administration. ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain. ' 'Accessed 30 Nov 2021.'}, { 'key': '6649_CR19', 'doi-asserted-by': 'publisher', 'first-page': '104760', 'DOI': '10.1016/j.antiviral.2020.104760', 'volume': '177', 'author': 'SNY Yang', 'year': '2020', 'unstructured': 'Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. ' 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760. ' 'https://doi.org/10.1016/j.antiviral.2020.104760.', 'journal-title': 'Antiviral Res'}, { 'key': '6649_CR20', 'doi-asserted-by': 'publisher', 'unstructured': 'Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. ' 'Ivermectin for the treatment of COVID-19: a systematic review and ' 'meta-analysis of randomized controlled trials. Clin Infect Dis. ' '2021;ciab591. https://doi.org/10.1093/cid/ciab591.', 'DOI': '10.1093/cid/ciab591'}, { 'key': '6649_CR21', 'doi-asserted-by': 'publisher', 'first-page': '300060521101355', 'DOI': '10.1177/03000605211013550', 'volume': '49', 'author': 'R Mahmud', 'year': '2021', 'unstructured': 'Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir AKMH, Sayeed SKJB, et al. ' 'Ivermectin in combination with doxycycline for treating COVID-19 ' 'symptoms: a randomized trial. J Int Med Res. 2021;49:3000605211013550. ' 'https://doi.org/10.1177/03000605211013550.', 'journal-title': 'J Int Med Res'}, { 'key': '6649_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e0242184', 'DOI': '10.1371/journal.pone.0242184', 'volume': '15', 'author': 'D Camprubí', 'year': '2020', 'unstructured': 'Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, ' 'Subirà C, et al. Lack of efficacy of standard doses of ivermectin in ' 'severe COVID-19 patients. PLoS One. 2020;15:e0242184. ' 'https://doi.org/10.1371/journal.pone.0242184.', 'journal-title': 'PLoS One'}, { 'key': '6649_CR23', 'doi-asserted-by': 'publisher', 'first-page': '100684', 'DOI': '10.1016/j.nmni.2020.100684', 'volume': '35', 'author': 'R Choudhary', 'year': '2020', 'unstructured': 'Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin ' 'and azithromycin drugs in fighting COVID-19: trends, scope and ' 'relevance. New Microbes New Infect. 2020;35:100684. ' 'https://doi.org/10.1016/j.nmni.2020.100684.', 'journal-title': 'New Microbes New Infect'}, { 'key': '6649_CR24', 'doi-asserted-by': 'publisher', 'unstructured': 'Hashim HA, et al. Controlled randomized clinical trial on using ' 'ivermectin with doxycycline for treating COVID-19 patients in Baghdad, ' 'Iraq. medRxiv. 2020. https://doi.org/10.1101/2020.10.26.20219345 ' '[Preprint 27 October 2020].', 'DOI': '10.1101/2020.10.26.20219345'}, { 'key': '6649_CR25', 'doi-asserted-by': 'publisher', 'first-page': '100720', 'DOI': '10.1016/j.eclinm.2020.100720', 'volume': '32', 'author': 'C Chaccour', 'year': '2021', 'unstructured': 'Chaccour C, et al. The effect of early treatment with ivermectin on ' 'viral load, symptoms and humoral response in patients with non-severe ' 'COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical ' 'trial. EClinicalmedicine. 2021;32:100720.', 'journal-title': 'EClinicalmedicine'}, { 'key': '6649_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1007', 'DOI': '10.1016/j.clinthera.2021.04.007', 'volume': '43', 'author': 'L Shahbaznejad', 'year': '2021', 'unstructured': 'Shahbaznejad L, Davoudi A, Eslami G, Markowitz J, Navaeifar M, ' 'Hosseinzadeh F, et al. Effects of ivermectin in patients with COVID-19: ' 'a multicenter, double-blind, randomized, controlled clinical trial. Clin ' 'Ther. 2021;43:1007–19. https://doi.org/10.1016/j.clinthera.2021.04.007.', 'journal-title': 'Clin Ther'}, { 'key': '6649_CR27', 'doi-asserted-by': 'publisher', 'first-page': '411', 'DOI': '10.1186/s12879-021-06104-9', 'volume': '21', 'author': 'O Nurullah', 'year': '2021', 'unstructured': 'Nurullah O, Demirtürk N, Çetinkaya R, Güner R, Avcı I, Orhan S, et al. ' 'Evaluation of the effectiveness and safety of adding ivermectin to ' 'treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21:411. ' 'https://doi.org/10.1186/s12879-021-06104-9.', 'journal-title': 'BMC Infect Dis'}, { 'key': '6649_CR28', 'doi-asserted-by': 'publisher', 'first-page': '214', 'DOI': '10.1016/j.ijid.2020.11.191', 'volume': '103', 'author': 'S Ahmed', 'year': '2021', 'unstructured': 'Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A ' 'five-day course of ivermectin for the treatment of COVID-19 may reduce ' 'the duration of illness. Int J Infect Dis. 2021;103:214–6. ' 'https://doi.org/10.1016/j.ijid.2020.11.191.', 'journal-title': 'Int J Infect Dis'}, { 'key': '6649_CR29', 'doi-asserted-by': 'publisher', 'unstructured': 'Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, et al. ' 'Ivermectin as a potential treatment for mild to moderate COVID-19 - a ' 'double blind randomized placebo-controlled trial. medRxiv. 2021. ' 'https://doi.org/10.1101/2021.01.05.21249310 [Preprint 9 January 2021].', 'DOI': '10.1101/2021.01.05.21249310'}, { 'key': '6649_CR30', 'doi-asserted-by': 'publisher', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'volume': '73', 'author': 'F Heidary', 'year': '2020', 'unstructured': 'Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral ' 'effects to COVID-19 complementary regimen. J Antibiot (Tokyo). ' '2020;73:593–602. https://doi.org/10.1038/s41429-020-0336-z.', 'journal-title': 'J Antibiot (Tokyo)'}], 'container-title': 'Trials', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s13063-022-06649-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s13063-022-06649-3/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s13063-022-06649-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 8, 26]], 'date-time': '2022-08-26T12:19:00Z', 'timestamp': 1661516340000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06649-3'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 8, 26]]}, 'references-count': 30, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['6649'], 'URL': 'http://dx.doi.org/10.1186/s13063-022-06649-3', 'relation': {}, 'ISSN': ['1745-6215'], 'subject': ['Pharmacology (medical)', 'Medicine (miscellaneous)'], 'container-title-short': 'Trials', 'published': {'date-parts': [[2022, 8, 26]]}, 'assertion': [ { 'value': '23 February 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '7 August 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '26 August 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The study was conducted according to the guidelines of the Declaration of ' 'Helsinki and Good Clinical Practice Guidelines. The trial was approved by the ' 'Vajira Ethics Committee, approval no 171/64. Written informed consent was ' 'obtained from all subjects involved in the study.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Consent for publication is not applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare they have no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '714'}